文献速递小儿眼科与斜弱视

左旋多巴/卡比多巴辅助治疗弱视:美国眼科学会报告

Levodopa/Carbidopa to Augment the Treatment of Amblyopia: A Report by the American Academy of Ophthalmology.
PubMed 文献 · Ophthalmology · 2023-08-29

美国眼科学会系统综述了左旋多巴/卡比多巴辅助治疗弱视的文献,检索PubMed至2022年10月,纳入12项研究(9项I级、3项II级证据)。左旋多巴剂量1.5-8.3 mg/kg/天、疗程3-16周,辅助遮盖可小幅改善弱视儿童视力(0.17-0.3 logMAR单位),但仅2/12研究较单纯遮盖有统计学显著差异,多数研究停药后视力回退,证据不足以证明有意义的视力改善。

要点

  • 左旋多巴/卡比多巴辅助遮盖在部分研究中可小幅改善弱视儿童视力,效应量0.17-0.3 logMAR单位。
  • 12项研究中仅2项显示较单纯遮盖有统计学显著差异,总体证据不足以证明有意义的视力改善。
  • 9/12研究报告停药后视力回退(范围0-0.17 logMAR单位),长期治疗有迟发性运动障碍潜在风险。

核心结论

  • 目前最佳证据不足以表明使用长达16周的左旋多巴/卡比多巴辅助弱视治疗能带来有意义的视力改善。
  • 鉴于长期治疗可能出现迟发性运动障碍等显著副作用,左旋多巴/卡比多巴似乎不是弱视治疗的可行选择。

研究设计与样本

  • 美国眼科学会报告,通过PubMed数据库检索截至2022年10月的英文文献,无日期限制。
  • 检索共获得55篇文章,其中23篇进行全文审阅,12篇被认为适合纳入本评估。
  • 由小组方法学家进行证据等级评定:9项研究为I级,3项研究为II级,无III级研究。

主要发现

  • 由于担心迟发性运动障碍等长期不良反应,治疗持续时间限于3至16周,但所有研究参与者中均未报告该并发症。
  • 左旋多巴剂量范围为1.5至8.3 mg/kg/天,通常分为每日3次给药;卡比多巴剂量在所有治疗中约为左旋多巴剂量的25%。
  • 研究证据表明,在传统遮盖治疗基础上口服左旋多巴/卡比多巴可改善弱视儿童视力,但效应较小(0.17-0.3 logMAR单位),且仅在12项研究中的2项中较单纯遮盖有统计学显著差异。
  • 大多数研究(12项中9项报告)报告停药后视力回退,回退范围为0-0.17 logMAR单位。
  • 药物短期副作用报告不一致,但最常见为轻度,包括头痛和恶心。

关键数值与推荐

  • 左旋多巴剂量1.5至8.3 mg/kg/天,通常分每日3次给药。
  • 卡比多巴剂量约为左旋多巴剂量的25%。
  • 治疗持续时间限于3至16周。
  • 视力改善效应量为0.17-0.3 logMAR单位,仅12项研究中2项较单纯遮盖有统计学显著差异。
  • 停药后视力回退范围0-0.17 logMAR单位。

临床怎么用

  • 原文结论指出,目前最佳证据不足以表明长达16周的左旋多巴/卡比多巴辅助治疗能带来有意义的视力改善。
  • 原文结论指出,鉴于长期治疗可能出现迟发性运动障碍等显著副作用,左旋多巴/卡比多巴似乎不是弱视治疗的可行选择。

局限性

  • 药物短期副作用报告不一致。
  • 仅12项研究中2项较单纯遮盖有统计学显著差异。
  • 目前最佳证据不足以表明能带来有意义的视力改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To review the published literature on the use of levodopa/carbidopa to augment the treatment of amblyopia. METHODS: Literature searches for English language studies were last conducted in October 2022 in the PubMed database with no date restrictions. The combined searches yielded 55 articles, of which 23 were reviewed in full text. Twelve of these were considered appropriate for inclusion in this assessment and were assigned a level of evidence rating by the panel methodologist. Nine studies were rated level I, and 3 studies were rated level II; there were no level III studies. RESULTS: The duration of treatment was limited to 3 to 16 weeks because of concern about long-term adverse effects such as tardive dyskinesia. This complication was not reported in any of the study participants. The dose of levodopa ranged from 1.5 to 8.3 mg/kg/day, generally divided into 3 daily doses. The carbidopa dose was approximately 25% of the levodopa dose in all treatments. Evidence from these studies indicates that augmenting traditional patch occlusion therapy with the oral administration of levodopa/carbidopa can improve the vision of amblyopic children, but the effect was small (0.17-0.3 logarithm of the minimum angle of resolution [logMAR] units) and only statistically significant when compared with patching alone in 2 of the 12 studies cited. Regression of vision was reported in the majority of studies (9 of 12 reported; range, 0-0.17 logMAR unit regression) after discontinuation of therapy. Short-term side effects of the medications were not consistently reported but were most frequently mild and included headache and nausea. CONCLUSIONS: The best available evidence is currently insufficient to show that augmenting amblyopia therapy using up to 16 weeks of levodopa/carbidopa will result in meaningful improvement in visual acuity. Given the potential for significant side effects such as tardive dyskinesia with long-term therapy, levodopa/carbidopa does not appear to be a viable option for amblyopia therapy FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Morrison DG, Heidary G, Chang MY, et al. Levodopa/Carbidopa to Augment the Treatment of Amblyopia: A Report by the American Academy of Ophthalmology. Ophthalmology. 2023. PMID: 37642618. doi:10.1016/j.ophtha.2023.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。